checkAd

     179  0 Kommentare TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock - Seite 3

    Investor and Media Contact:

    Lesen Sie auch

    Carl Mauch
    Director, Investor Relations and Corporate Communications
    TCR2 Therapeutics Inc.
    (617) 949-5667
    carl.mauch@tcr2.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock - Seite 3 CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) - TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today …